Medical/Pharmaceuticals News & Press Release Distribution

NaviFUS begins FUS combined with radiotherapy clinical trial for the treatment of terminal primary brain tumors

TAIPEI, Aug. 4, 2021 /PRNewswire/ -- NaviFUS' focused ultrasound (FUS) therapy system (NaviFUS®) was recently approved for use in a new clinical trial by the Taiwan Food and Drug Administration (TFDA). It will be initiated shortly at Linkou Chang Gung Memorial Hospital. The trial will investigate...

2021-08-04 11:50 1550

TIENS Group will Become a Global Participant in the Future Massive Health Industry

TIANJIN, China, Aug. 4, 2021 /PRNewswire/ -- As announced proudly by TIENS Group's Chairman Li Jinyuan in theHealth Industry Development Forum of the Belt and Road in the Post-pandemic Era held in Tianjin, China, TIENS Group is poised to become one of main global participants in the future massiv...

2021-08-04 00:40 2270

TIENS Group will Become a Global Participant in the Future Massive Health Industry

Lumosa Therapeutics Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke

* LT3001 met primary safety endpoint. No symptomatic intracranial hemorrhage occurred. * LT3001 showed pronounced neurological improvement in the majority of patients with baseline NIHSS≥6 treated with LT3001. * These data suggest that LT3001 has the potential to provide significant clinica...

2021-08-03 22:48 1577

Varigard Technologies Proven to Prevent the Tactile Spread of SARS-CoV-2, B.1.617.2 - DELTA Variant

Varigard's protective Hand Sanitizing lotion prevents the tactical spread of SARS-CoV-2, B.1.617.2 for two hours and for over 20 hours with its organic Surface Spray FOLEY, Ala., Aug. 3, 2021 /PRNewswire/ -- Varigard and Synergy Laboratories have announced the test results of an advanced hand sa...

2021-08-03 22:00 1511

Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®

SEOUL, South Korea, Aug. 3, 2021 /PRNewswire/ -- Yuyu Pharma, a pharmaceutical company based in Korea, and Novartis Korea announced today that the companies have entered into an agreement in which Yuyu will have exclusive distribution rights for the following prescription medicines in Korea: Lami...

2021-08-03 21:00 1588

Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®

Pulnovo Medical, a pioneer medical device company, specializing in the treatment of pulmonary artery hypertension, recently raised millions of dollars through OrbiMed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures(LAV), and GaoRong Capital

NANJING, China, Aug. 3, 2021 /PRNewswire/ -- Pulnovo Medical, a pioneer medical device company, specializing in the treatment of pulmonary artery hypertension, recently raised millions of dollars through OrbiMed, Cenova, Lilly Asia Ventures (LAV), and GaoRong Capital. Funds raised in this round w...

2021-08-03 20:32 1881

CartiHeal Announces Pivotal Study Results Demonstrate Agili-C™ Superiority to Microfracture and Debridement for the Treatment of Cartilage and Osteochondral Defects

According to a Two-Year Randomized and Controlled Multinational IDE Study KFAR SABA, Israel, Aug. 3, 2021 /PRNewswire/ -- CartiHeal Ltd, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, which was granted Breakthrough Device...

2021-08-03 20:06 1839

$CartiHeal Announces Pivotal Study Results Demonstrate Agili-C™ Superiority to Microfracture and Debridement for the Treatment of Cartilage and Osteochondral Defects$

111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China

SHANGHAI, Aug. 3, 2021 /PRNewswire/ – 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced a strategic cooperation agreement with Suzhou Zelgen ...

2021-08-03 20:00 7533

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Yvelise Barrios, MD, PhD, Immunologist and leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behindCoviDTH, joins BioVaxys as scientific adviser VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (C...

2021-08-03 20:00 4603

TCM Lianhua Qingwen shows stable in vitro antiviral effect on the Delta variant: Expert

GUANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- The latest research findings from the team of Professor Yang Zifeng from the State Key Laboratory of Respiratory Disease inGuangzhou, China, have showed that Chinese medicine Lianhua Qingwen has an effective inhibitory action on the Delta variant of ...

2021-08-03 15:27 2446

Nanoform and Boehringer Ingelheim execute master services agreement

HELSINKI, Aug. 3, 2021 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform's award-winning CESS® technology can deliver to its drug development proj...

2021-08-03 14:28 1938

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor

BEIJING, Aug. 3, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 inChina. JAB-21822 is Jacobio's innovative in-house small molecule anti-cancer drug, which is designed to target t...

2021-08-03 09:00 2629

CStone announces positive registrational study of the first-in-class drug ivosidenib in Chinese patients with relapsed or refractory acute myeloid leukemia, and NDA has been accepted by the China NMPA and considered for Priority Review

* Ivosidenib (TIBSOVO®, the brand name in the U.S.) is the first isocitrate dehydrogenase 1 (IDH1) inhibitor inChina that has demonstrated its efficacy and manageable safety in patients with relapsed or refractory acute myeloid leukemia (R/R AML) * The National Medical Products Administration...

2021-08-03 08:05 3078

Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus

HANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- Insilico Medicine and Westlake Pharma announced a strategic partnership to jointly develop innovative small-molecule drugs for Novel Coronavirus (COVID-19) today. Insilico Medicin...

2021-08-03 08:00 32761

Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus

Cardinal Health completes sale of Cordis business to Hellman & Friedman

DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health's Cordis business to H&F. The sale price of approximately$1 billion includes the buyer's assumption of certain lia...

2021-08-02 23:00 3150

Cardinal Health completes sale of Cordis business to Hellman & Friedman

DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health's Cordis business to H&F. The sale price of approximately$1 billion includes the buyer's assumption of certain lia...

2021-08-02 23:00 3299

SI Group Ranks in the Top 5 Percent for Global Corporate Social Responsibility

Company Awarded Gold Rating by EcoVadis for its Sustainability Commitment SCHENECTADY, N.Y., Aug. 2, 2021 /PRNewswire/ -- SI Group, a global leader in the innovative technology of performance additives, process solutions, active pharmaceutical ingredients, and chemical intermediates, has received...

2021-08-02 22:33 2105

SI Group Ranks in the Top 5 Percent for Global Corporate Social Responsibility

Vision Impact Institute Applauds UN Resolution on Vision

Resolution highlights impact of good vision to achieving the Sustainable Development Goals DALLAS, Aug. 2, 2021 /PRNewswire/ -- The Vision Impact Institute applauds the UN General Assembly's adoption of theVision for Everyone: accelerating action to achieve the Sustainable Development Goals reso...

2021-08-02 22:30 1736

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate

SUZHOU, China, Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP c...

2021-08-02 20:13 2837

Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

* Nitric oxide has antimicrobial properties with direct proven effect on SARS-CoV-2 * Nitric Oxide Nasal Spray (NONS) has been tested in healthy volunteers and patients as part of UK andCanada clinical trials1 MUMBAI, India and VANCOUVER, BC, Aug. 2, 2021 /PRNewswire/ -- Glenmark Pharmaceutic...

2021-08-02 18:45 2768